Developing Story
Halozyme v. MSD Keytruda Patent Dispute
A Dutch court ruled in favor of Halozyme over MSD regarding patent EP 2 797 622 related to cancer drug Keytruda, dismissing MSD's revocation action and granting Halozyme infringement findings across eight European jurisdictions (October 9, 2026). The case strengthens Halozyme's IP position against one of the world's top-selling cancer therapies.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
Halozyme has won a significant patent ruling against MSD (Merck & Co.) over its blockbuster cancer drug Keytruda. On October 9, 2026, a Dutch court dismissed MSD's revocation action against the Dutch part of European patent EP 2 797 622 and granted Halozyme's counterclaims for infringement covering multiple jurisdictions, including Belgium, Denmark, France, Ireland, Italy, the Netherlands, Sweden, and Switzerland (case ID: C/09/695432 / HA ZA 25-1075) (JUVE Patent, October 9).
The panel—judges Edger Brinkman, Jorrit Hoefnagel and Carolin Schüller—ruled against MSD's position, strengthening Halozyme's intellectual property position across major European markets (JUVE Patent, October 9). The ruling is notable as an example of a unified pan-European patent enforcement action and could have implications for how Keytruda, one of the world's best-selling cancer drugs, is manufactured or licensed in Europe, as well as for Halozyme's drug-delivery technology licensing business more broadly.